AzTrials
AzTrials

Adolescent Idiopathic ScoliosisPhase 4NCT04950660

Oral Caffeine Use for Pain Management in AIS Patients After Spinal Fusion

A Phase 4 study testing Caffeine Tablet in people with Adolescent Idiopathic Scoliosis, run by Children's Mercy Hospital Kansas City at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Prospective, randomized control trial To determine if oral caffeine decreases the frequency of opioid demand in children with adolescent idiopathic scoliosis after their spinal fusion surgery To compare pain scale ratings, number of requests for diazepam, average heart rate, average blood pressure, sex, age… Read more about this study

Who is it for?
Ages 12 to 17 years
Conditions the study is for
Adolescent Idiopathic Scoliosis
What is being tested?
Caffeine Tablet
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
61 participants
Where
1 siteUnited States
Study dates
11 Dec 2019to 1 Aug 2024
Phase
Phase 4
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 12 to 17 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • must meet criteria for surgical correction of scoliosis
  • must be able to swallow pills
  • must have English as a primary language
  • must possess mental capacity to understand purpose of the study
  • patient must carry diagnosis of adolescent idiopathic scoliosis
  • surgery must be performed via posterior approach
Show all 11Show fewer
  • operation performed by either Dr. John T. Anderson, Dr. Richard M. Schwend, Dr. Aaron Shaw, Dr. Michael Benvenuti
  • post-surgical AIS patients from June 2019-June 2024
  • the patient must be between the ages of 12 and 17 years old
  • the patient and one of their biological parents or guardian(s) must give consent for patient to be included in this study
  • Negative Suicide screen

Who cannot join

  • obesity, as defined by a BMI at or above the 95th percentile
  • weight below 40 kg
  • any orthopedic diagnosis other than AIS
  • revision spine surgery
  • anterior or combined approach
  • admission to PICU post-op
Show all 21Show fewer
  • use of Oxycodone post-op
  • allergies to ibuprofen, caffeine, codeine, or diazepam
  • history of renal disease
  • history of a coagulation disorder
  • history of cardiac dysrhythmia or open heart surgery
  • history of Chronic Pain Syndrome or Complex Regional Pain Syndrome
  • current use of oral central nervous system stimulant (e.g. methylphenidate)
  • Positive Suicide screen
  • The following populations will be excluded:
  • Children over the age of 18, or turning 18 during time of surgical treatment
  • Children or parents unable to consent
  • Individuals with cognitive delays
  • Pregnant females
  • Prisoners
  • Wards of the state

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Children'S Mercy Hospitals & Clinic

    Kansas City, Missouri, 64114

Other trials in United States

About this study

Official title: Oral Caffeine Decreases the Frequency of Opioid Demand in AIS Patients After Spinal Fusion

Prospective, randomized control trial To determine if oral caffeine decreases the frequency of opioid demand in children with adolescent idiopathic scoliosis after their spinal fusion surgery To compare pain scale ratings, number of requests for diazepam, average heart rate, average blood pressure, sex, age, ethnicity, post-op day of discharge, operative time, estimated intraoperative blood loss, remittance post-surgery, length of hospital stay, and segments fused during spinal fusion surgery.

Read the detailed description

Because these receptors are so important for modifying pain and inflammation, caffeine has been added as an adjuvant to common analgesics, such as paracetamol, ibuprofen, and aspirin in the belief that it will enhance their analgesic efficacy. Most studies used paracetamol or ibuprofen with 100 mg to 130 mg caffeine, and the most common pain conditions studied were postoperative dental pain, postpartum pain, and headache. There was a small but statistically significant benefit with caffeine used at doses of 100 mg or more, which was not dependent on the pain condition or type of analgesic. Additionally, trials have shown superior efficacy of adding caffeine to ibuprofen instead of administering ibuprofen alone for treating acute pain, reflecting that caffeine is an effective analgesic adjuvant. The addition of caffeine (≥ 100 mg) to a standard dose of commonly used analgesics provides a small but important increase in the proportion of participants who experience a good level of pain relief.

Finally, the beneficial effects of caffeine on aerobic activity and resistance training performance are well documented. Studies have shown that caffeine ingestion resulted in significantly lower levels of soreness compared with placebo (p ≤ 0.05). A further beneficial effect of sustained caffeine ingestion in the days after the exercise bout is an attenuation of delayed onset muscle soreness. Orthopaedic surgery also causes muscle injury, and patients might benefit from caffeine's effect on lowering muscle soreness. Acute caffeine administration also has been shown to demonstrate increases in alertness, contentment, motivation to work, talkativeness, and energy. It also decreases muscle twitches. All of these effects would be beneficial in the post-operative period, especially for Adolescence Idiopathic Scoliosis (AIS) patients undergoing spinal fusion surgery in the orthopaedic department at Children's Mercy Hospital.

Being tested
Caffeine Tablet, Placebo

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Caffeine TabletDrug

    Also called Caffeine

    Caffeine is approved by the FDA as a stimulant. A stimulant approved by the United States Food and Drug Administration (FDA) for the treatment to increase mental alertness and in combination with painkiller to treat migraine headaches. It is approved in the form of pill or tablet.

  • PlaceboDrug

    Also called Blank

    Placebo, empty opaque dark blue blank capsule, taken twice daily. This will be an adjuvant to their standard pain control.

Study groups in NCT04950660
Study groupRoleWhat they receive
Caffeine armActive comparatorExperimental Group: patient group (n = 34) receiving a 100 mg dose of caffeine (1/2 of a 200mg tablet to be taken whole or crushed), taken twice daily. This will be an adjuvant to their standard pain control.
Receives: Drug: Caffeine Tablet
Placebo armPlacebo comparatorControl group: patient group (n = 34) receiving placebo compounded to look similar to the caffeine treatment, taken twice daily. This will be an adjuvant to their standard pain control.
Receives: Drug: Caffeine Tablet; Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Total Post Operative Oral Morphine Milligram Equivalents (MME)/Kilogram (Kg) for Hospital Stay

    Total Post Operative Oral Morphine milligram equivalents (MME)/kilogram (Kg) for Hospital Stay

    Measured: For hospital stay up to 7 days

Secondary outcomes (3)
  1. Mean Daily Verbal Analog Scale (VAS)

    Utilizing Verbal Analog Scale 0-10, 0 being no pain and 10 being severe pain

    Measured: For hospital stay up to 7 days

  2. Average Heart Rate During Hospital Stay

    Documented heart rates which are then averaged over 24 hours

    Measured: For hospital stay up to 7 days

  3. Average Systolic Blood Pressure During Hospital Stay

    Documented systolic blood pressures which are then averaged over 24 hours

    Measured: For hospital stay up to 7 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Jul 2021
  2. Study start11 Dec 2019
  3. Primary completion20 Jan 2024
  4. Study completion1 Aug 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Model description
This study will be a prospective, randomized control trial and will be double-blinded, with the patient, provider, and researcher blinded to the treatment.
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
61 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04950660
Sponsor's protocol ID
STUDY00000775
Status last verified
Jan 2025
First submitted
15 Jun 2021
Last updated
21 Feb 2025
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No: only the research team will have access to study results. No IPD will be shared with anyone outside of the research team.

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Caffeine Tablet in people with Adolescent Idiopathic Scoliosis, run by Children's Mercy Hospital Kansas City at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 21 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 21 Feb 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Total Post Operative Oral Morphine Milligram Equivalents (MME)/Kilogram (Kg) for Hospital Stay (time frame: For hospital stay up to 7 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Feb 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in